NO20076344L - Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren - Google Patents

Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren

Info

Publication number
NO20076344L
NO20076344L NO20076344A NO20076344A NO20076344L NO 20076344 L NO20076344 L NO 20076344L NO 20076344 A NO20076344 A NO 20076344A NO 20076344 A NO20076344 A NO 20076344A NO 20076344 L NO20076344 L NO 20076344L
Authority
NO
Norway
Prior art keywords
agonists
piperazine
ht1a receptor
compounds
ht1a
Prior art date
Application number
NO20076344A
Other languages
English (en)
Inventor
Magda Asselin
George Theodore Grosu
Annmarie L Sabb
Wayne Everett Childers
Lisa Marie Havran
Zhongui Shen
James Jacob Bicksler
Dan Chaekoo Chong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20076344L publication Critical patent/NO20076344L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye piperazin-piperidin-forbindelser. Forbindelsene er anvendelige som 5-HT1A bindemidler, spesielt som 5-HT1A reseptorantagonister og -agonister. Disse forbindelser er anvendelige for behandling av sentralnervesystem-lidelser, så som kognisjons-lidelser, angst-lidelser, depresjon og seksuell dysfunksjon.
NO20076344A 2005-06-10 2007-12-11 Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren NO20076344L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68946905P 2005-06-10 2005-06-10
PCT/US2006/022719 WO2006135839A2 (en) 2005-06-10 2006-06-09 Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor

Publications (1)

Publication Number Publication Date
NO20076344L true NO20076344L (no) 2008-02-27

Family

ID=37530084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076344A NO20076344L (no) 2005-06-10 2007-12-11 Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren

Country Status (20)

Country Link
US (1) US7671056B2 (no)
EP (1) EP1888559A2 (no)
JP (1) JP2008543782A (no)
KR (1) KR20080021134A (no)
CN (1) CN101243073A (no)
AR (1) AR055059A1 (no)
AU (1) AU2006257874A1 (no)
BR (1) BRPI0613491A2 (no)
CA (1) CA2611711A1 (no)
CR (1) CR9560A (no)
EC (1) ECSP088094A (no)
GT (1) GT200600255A (no)
IL (1) IL187972A0 (no)
MX (1) MX2007015678A (no)
NO (1) NO20076344L (no)
PE (1) PE20070069A1 (no)
RU (1) RU2007146543A (no)
TW (1) TW200800959A (no)
WO (1) WO2006135839A2 (no)
ZA (1) ZA200710699B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808730A (en) * 2006-06-09 2008-02-16 Wyeth Corp Process for synthesizing piperazine-piperidine compounds
CN101466365A (zh) * 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
US20080199518A1 (en) * 2006-11-28 2008-08-21 Wyeth Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
PA8769901A1 (es) * 2007-02-16 2008-11-19 Wyeth Corp Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina-piperidina del receptor 5-ht1a que tienen disolucion intestinal mejorada
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
CN101797223B (zh) * 2009-02-06 2012-05-23 上海交通大学医学院 石杉碱甲眼用制剂及其应用
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA2804215C (en) * 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2908952C3 (de) 1979-03-07 1981-12-03 Gerhard Hug Gmbh, 7801 Umkirch Drainagevorrichtung
US4624954A (en) 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US4665183A (en) 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US5219857A (en) 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
ES2130135T3 (es) 1990-01-11 1999-07-01 Upjohn Co Nuevos compuestos heterociclicos de 6,7,8,9-tetrahidro-3h-benz(e)indol con actividad terapeutica sobre el sistema nervioso central.
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9125615D0 (en) 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
ATE253909T1 (de) 1992-07-24 2003-11-15 Univ California Arzneimittel die den durch ampa rezeptoren vermittelten synaptischen response erhöhen
EP0959074A3 (en) 1992-12-17 2000-06-07 Pfizer Inc. Substituted pyrazoles as CRF antagonists
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
KR0170567B1 (ko) 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
RU2185372C2 (ru) 1996-05-31 2002-07-20 Фармация Энд Апджон Компани Алкилзамещенные циклические амины в качестве селективных лигандов d3-допамина
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
SE9804126D0 (sv) 1998-11-27 1998-11-27 Astra Ab New pharmaceutical composition
DK1147083T3 (da) 1999-01-07 2004-08-16 Wyeth Corp Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
CA2405089A1 (en) 2000-04-10 2001-10-18 Pfizer Products Inc. Benzoamide piperidine containing compounds and related compounds
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
KR100869061B1 (ko) 2000-12-13 2008-11-17 와이어쓰 베타 아밀로이드 생성의 헤테로고리 술폰아미드 저해제
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
WO2002088145A1 (en) 2001-04-26 2002-11-07 Wyeth AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS
WO2002088132A1 (en) 2001-04-26 2002-11-07 Wyeth Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-ht1aantagonists
AR035083A1 (es) 2001-07-25 2004-04-14 Wyeth Corp Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
CA2484936A1 (en) 2002-05-08 2004-05-21 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
US20040063721A1 (en) 2002-08-15 2004-04-01 Wyeth Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004045718A2 (en) 2002-11-20 2004-06-03 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
US7276603B2 (en) 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
DE602004008474T2 (de) 2003-07-31 2008-05-15 Wyeth N-sulfonylheterocyclopyrrolylalkylamin-verbindungen als 5-hydroxytryptamin-6-liganden.
PT1541197E (pt) 2003-12-02 2009-06-04 Pharmaneuroboost N V Utilização de pipamperona e de um sndri, snri ou ssri para o tratamento de patologias do temperamento ou da ansiedade
MY179926A (en) 2003-12-08 2020-11-19 Wyeth Corp Process for the preparation of tubulin inhibitors
JP2007537151A (ja) 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
EP1720886A1 (en) 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
WO2005084673A1 (en) 2004-03-02 2005-09-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
US20050215561A1 (en) 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
TWI391387B (zh) 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
ATE444962T1 (de) 2004-06-16 2009-10-15 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
MXPA06014792A (es) 2004-06-16 2007-02-16 Wyeth Corp Difenilimidazopirimidina y aminas imidazol como inhibidores de ??-secretasa.
WO2006042249A2 (en) 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
EP1853230A2 (en) 2005-02-15 2007-11-14 Jazz Pharmaceuticals Inc. Dosage form and method for sustained release of a substituted pyrazine compound
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
JP4796927B2 (ja) 2005-11-28 2011-10-19 株式会社豊田中央研究所 クロック信号出力回路
TW200808741A (en) 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808730A (en) 2006-06-09 2008-02-16 Wyeth Corp Process for synthesizing piperazine-piperidine compounds
CN101466365A (zh) 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
TW200808740A (en) 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
US20080199518A1 (en) 2006-11-28 2008-08-21 Wyeth Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution

Also Published As

Publication number Publication date
US20070027160A1 (en) 2007-02-01
MX2007015678A (es) 2008-02-20
WO2006135839A2 (en) 2006-12-21
EP1888559A2 (en) 2008-02-20
KR20080021134A (ko) 2008-03-06
CA2611711A1 (en) 2006-12-21
TW200800959A (en) 2008-01-01
ZA200710699B (en) 2009-05-27
CN101243073A (zh) 2008-08-13
AU2006257874A1 (en) 2006-12-21
AR055059A1 (es) 2007-08-01
RU2007146543A (ru) 2009-07-20
WO2006135839A3 (en) 2007-11-22
IL187972A0 (en) 2008-03-20
BRPI0613491A2 (pt) 2011-01-11
JP2008543782A (ja) 2008-12-04
US7671056B2 (en) 2010-03-02
GT200600255A (es) 2007-07-19
CR9560A (es) 2008-02-20
PE20070069A1 (es) 2007-03-15
ECSP088094A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
NO20073182L (no) Indazol-karboksamidforbindelser
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
TNSN07196A1 (en) Potentiators of glutamate receptors
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
ATE495171T1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
DK2178858T3 (da) Nye heterocycliske forbindelser som mGlu5-antagonister
GT200800052A (es) Compuestos triciclicos utiles como agonistas de recepciones de oxitocina
DE602006020450D1 (de) Ykinin-rezeptorantagonisten
MX2007010769A (es) Compuestos de quinolina como agonistas de receptor 5-ht4.
TW200736240A (en) Novel processes for the preparation of cyclopropyl-amide derivatives
ATE449077T1 (de) Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes
NO20082459L (no) Nye prosesser for fremstilling av piperazinyl og diazapanylbenzamidderivater
DK2016064T3 (da) Fremgangsmåder til fremstilling af pyrazolholdige forbindelser
DK1893597T3 (da) AMPA-receptorpotentiatorer
TW200716602A (en) Novel compounds
SE0403005D0 (sv) New use
TW200738646A (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application